Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Healthcare Reports | Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas

Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas

In 2008, the six tumor types covered in this report are forecast to account for over 961,000 new cases of cancer. Collectively, the 32 different drugs in Phase III development for the six tumor types are forecast to achieve $4,789m in sales by 2017. This constitutes a significant proportion of the oncology market, thus representing ample commercial opportunities for drug developers.

Scope

*Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor types

*Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions

*Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication for six tumor types

*Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs

Highlights

Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and brivanib (BMS-582664; Bristol-Myers Squibb) show the most potential in the colorectal cancer pipeline. Aflibercept has shown activity following failure of prior standard Avastin (bevacizumab; Genentech/Roche), while brivanib's novel mechanism of action could represent a first-in-class therapy.

Melanoma is the most popular R&D target of the six tumor types covered in this report, due to persistent high unmet needs and a substantial incidence. Elesclomol (STA-4783; Synta Pharmaceuticals/GlaxoSmithKline) currently shows the most potential at present, although only if successful Phase II results can be replicated in Phase III studies.

First-line axitinib (AG-13736; Pfizer) and Gemzar (gemcitabine; Eli Lilly) showed similar response rates and overall survival to first-line Gemzar and Tarceva (erlotinib; Genentech/Roche) in pancreatic cancer. If this can be replicated in Phase III trials, approval is likely, given that Tarceva was approved based on a 2-week survival benefit.

Reasons to Purchase

*Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2017 and Datamonitor drug assessment

*Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to fulfil them

*Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products

19-Dec-08 PDF & SlidePack & DataPack Pages 265

Table of Contents
Price: $11,400.00 / €7,619.76

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions